中心性浆液性脉络膜视网膜病变的发病机制与治疗研究进展

doi:10.6040/j.issn.1673-3770.0.2022.032

Abstract

Abstract: Central serous chorioretinopathy(CSC), one of the most common causes of visual impairment among fundus oculi diseases, typically presents with central vision loss and micropsia. Having a type A personality, administration of exogenous glucocorticoids, and endogenous hypercortisolism have been recognized as risk factors for CSC. Fundus fluorescein angiography and indocyanine green angiography have shown that CSC may be secondary to choroidal vascular hyperpermeability and retinal pigment epithelial dysfunction. However, its exact pathophysiology and management remain unknown. Photodynamic and laser photocoagulation have been used as managements for patients with CSC. This article provides an overview of CSC's risk factors, pathogenesis, pathophysiology and treatments.

Key words: Central serous chorioretinopathy, Risk factors, Pathogenesis, Pathophysiology, Treatments

CLC Number:

R774.5

LI Lu, ZHAO Jie, ZHAO Bojun. Research progress on the pathogenesis and treatments of central serous chorioretinopathy[J].Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 118-124.

References

[1] Liu B, Deng T, Zhang JJ. Risk factors for central serous chorioretinopathy: a systematic review and meta-analysis[J]. Retina, 2016, 36(1): 9-19. doi:10.1097/IAE.0000000000000837
[2] Manayath GJ, Arora S, Parikh H, et al. Is myopia a protective factor against central serous chorioretinopathy? [J]. Int J Ophthalmol, 2016, 9(2): 266-270. doi:10.18240/ijo.2016.02.16
[3] Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study[J]. Invest Ophthalmol Vis Sci, 2006, 47(8): 3474-3478. doi:10.1167/iovs.05-1246
[4] 张新媛, 赖旭佑. 关注黄斑区肥厚型脉络膜疾病谱的概念及研究[J]. 中华实验眼科杂志, 2017, 35(5): 385-390. doi:10.3760/cma.j.issn.2095-0160.2017.05.001 ZHANG Xinyuan, LAI Xuyou. Paying attention to the concept and research of pachychoroid disease spectrum[J]. Chinese Journal of Experimental Ophthalmology, 2017, 35(5): 385-390. doi:10.3760/cma.j.issn.2095-0160.2017.05.001
[5] 王海燕, 王雨生. 值得关注的肥厚型脉络膜病变[J]. 眼科新进展, 2020, 40(3): 201-205. doi:10.13389/j.cnki.rao.2020.0048 WANG Haiyan, WANG Yusheng. Pachychoroidopathy: a novel subject deserving of deep exploration[J]. Recent Advances in Ophthalmology, 2020, 40(3): 201-205. doi:10.13389/j.cnki.rao.2020.0048
[6] Yannuzzi LA. Type A behavior and central serous chorioretinopathy[J]. Trans Am Ophthalmol Soc, 1986, 84: 799-845.
[7] Sibayan SA, Kobuch K, Spiegel D, et al. Epinephrine, but not dexamethasone, induces apoptosis in retinal pigment epithelium cells in vitro: possible implications on the pathogenesis of central serous chorioretinopathy[J]. Graefes Arch Clin Exp Ophthalmol, 2000, 238(6): 515-519. doi:10.1007/pl00007893
[8] Kim YK, Woo SJ, Park KH, et al. Association of central serous chorioretinopathy with psychosocial factors is dependent on its phase and subtype[J]. Korean J Ophthalmol, 2018, 32(4): 281-289. doi:10.3341/kjo.2017.0144
[9] Chen J, Wang ZZ, Zhang S, et al. Does mineralocorticoid receptor play a vital role in the development of depressive disorder? [J]. Life Sci, 2016, 152: 76-81. doi:10.1016/j.lfs.2016.03.022
[10] Daruich A, Matet A, Dirani A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis[J]. Prog Retin Eye Res, 2015, 48: 82-118. doi:10.1016/j.preteyeres.2015.05.003
[11] Zhao M, Célérier I, Bousquet E, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy[J]. J Clin Invest, 2012, 122(7): 2672-2679. doi:10.1172/JCI61427
[12] Weenink AC, Borsje RA, Oosterhuis JA. Familial chronic central serous chorioretinopathy[J]. Ophthalmologica, 2001, 215(3): 183-187. doi:10.1159/000050855
[13] van Dijk EHC, Schellevis RL, Breukink MB, et al. Familial central serous chorioretinopathy[J]. Retina, 2019, 39(2): 398-407. doi:10.1097/IAE.0000000000001966
[14] Giannopoulos K, Gazouli M, Chatzistefanou K, et al. The genetic background of central serous chorioretinopathy: a review on central serous chorioretinopathy genes[J]. J Genomics, 2021, 9: 10-19. doi:10.7150/jgen.55545
[15] Kaye R, Chandra S, Sheth J, et al. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities[J]. Prog Retin Eye Res, 2020, 79: 100865. doi:10.1016/j.preteyeres.2020.100865
[16] Mohabati D, Schellevis RL, van Dijk EHC, et al. Genetic risk factors in acute central serous chorioretinopathy[J]. Retina, 2019, 39(12): 2303-2310. doi:10.1097/IAE.0000000000002333
[17] Schellevis RL, van Dijk EHC, Breukink MB, et al. Exome sequencing in families with chronic central serous chorioretinopathy[J]. Mol Genet Genomic Med, 2019, 7(4): e00576. doi:10.1002/mgg3.576
[18] Nicholson BP, Atchison E, Idris AA, et al. Central serous chorioretinopathy and glucocorticoids: an update on evidence for association[J]. Surv Ophthalmol, 2018, 63(1): 1-8. doi:10.1016/j.survophthal.2017.06.008
[19] Tittl MK, Spaide RF, Wong D, et al. Systemic findings associated with central serous chorioretinopathy[J]. Am J Ophthalmol, 1999, 128(1): 63-68. doi:10.1016/s0002-9394(99)00075-6
[20] Haimovici R, Rumelt S, Melby J. Endocrine abnormalities in patients with central serous chorioretinopathy[J]. Ophthalmology, 2003, 110(4): 698-703. doi:10.1016/S0161-6420(02)01975-9
[21] Abalem MF, Machado MC, Santos HN, et al. Choroidal and retinal abnormalities by optical coherence tomography in endogenous Cushing's syndrome[J]. Front Endocrinol(Lausanne), 2016, 7: 154. doi:10.3389/fendo.2016.00154
[22] 王维亚. 中心性浆液性脉络膜视网膜病变中糖皮质激素、儿茶酚胺等的浓度变化[J]. 医学理论与实践, 2007, 20(10): 1185-1186. doi:10.19381/j.issn.1001-7585.2007.10.054
[23] Xu H, Huang LZ, Jin EZ, et al. Plasma metabolomic profiling of central serous chorioretinopathy[J]. Exp Eye Res, 2021, 203: 108401. doi:10.1016/j.exer.2020.108401
[24] Tewari HK, Gadia R, Kumar D, et al. Sympathetic-parasympathetic activity and reactivity in central serous chorioretinopathy: a case-control study[J]. Invest Ophthalmol Vis Sci, 2006, 47(8): 3474-3478. doi:10.1167/iovs.05-1246
[25] Chung YR, Kim JW, Kim SW, et al. Choroidal thickness in patients with central serous chorioretinopathy[J]. Retina, 2016, 36(9): 1652-1657. doi:10.1097/iae.0000000000000998
[26] Haimovici R, Koh S, Gagnon DR, et al. Risk factors for central serous chorioretinopathy: a case-control study[J]. Ophthalmology, 2004, 111(2): 244-249. doi:10.1016/j.ophtha.2003.09.024
[27] Imanaga N, Terao N, Nakamine S, et al. Scleral thickness in central serous chorioretinopathy[J]. Ophthalmol Retina, 2021, 5(3): 285-291. doi:10.1016/j.oret.2020.07.011
[28] Ersoz MG, Arf S, Hocaoglu M, et al. Patient characteristics and risk factors for central serous chorioretinopathy: an analysis of 811 patients[J]. Br J Ophthalmol, 2019, 103(6): 725-729. doi:10.1136/bjophthalmol-2018-312431
[29] 尤冉, 郭笑霄, 陈曦, 等. 高度近视患者视网膜和脉络膜形态结构研究[J]. 临床和实验医学杂志, 2018, 17(22): 2396-2400. doi:10.3969/j.issn.1671-4695.2018.22.013 YOU Ran, GUO Xiaoxiao, CHEN Xi, et al. Retinal and choroidal morphology in 32 patients with high myopia[J]. Journal of Clinical and Experimental Medicine, 2018, 17(22): 2396-2400. doi:10.3969/j.issn.1671-4695.2018.22.013
[30] Cilo glu E, Unal F, Dogan NC. The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels[J]. Graefes Arch Clin Exp Ophthalmol, 2018, 256(6): 1111-1116. doi:10.1007/s00417-018-3985-x
[31] Wickham LA, Gao J, Toda I, et al. Identification of androgen, estrogen and progesterone receptor mRNAs in the eye[J]. Acta Ophthalmol Scand, 2000, 78(2): 146-153. doi:10.1034/j.1600-0420.2000.078002146.x
[32] Rocha EM, Wickham LA, da Silveira LA, et al. Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues[J]. Br J Ophthalmol, 2000, 84(1): 76-84. doi:10.1136/bjo.84.1.76
[33] Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography[J]. Retina, 2011, 31(2): 332-335. doi:10.1097/IAE.0b013e3181eef0ae
[34] Kloos P, Laube I, Thoelen A. Obstructive sleep apnea in patients with central serous chorioretinopathy[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2008, 246(9): 1225-1228. doi:10.1007/s00417-008-0837-0
[35] McArdle N, Hillman D, Beilin L, et al. Metabolic risk factors for vascular disease in obstructive sleep apnea: a matched controlled study[J]. Am J Respir Crit Care Med, 2007, 175(2): 190-195. doi:10.1164/rccm.200602-270OC
[36] Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome[J]. Respiration, 2002, 69(3): 229-234. doi:10.1159/000063625
[37] Giusti C. Association of Helicobacter pylori with central serous chorioretinopathy: hypotheses regarding pathogenesis[J]. Med Hypotheses, 2004, 63(3): 524-527. doi:10.1016/j.mehy.2004.02.020
[38] Hu J, Qu JF, Piao ZY, et al. Optical coherence tomography angiography compared with indocyanine green angiography in central serous chorioretinopathy[J]. Sci Rep, 2019, 9(1): 6149. doi:10.1038/s41598-019-42623-x
[39] Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy[J]. Br J Ophthalmol, 2003, 87(6): 709-712. doi:10.1136/bjo.87.6.709
[40] 陈桂芬, 马景学, 王长龄, 等. 中心性浆液性脉络膜视网膜病变色素上皮功能状态分析[J]. 中国实用眼科杂志, 2008, 26(11): 1255-1256. doi:10.3760/cma.j.issn.1006-4443.2008.11.030 CHEN Guifen, MA Jingxue, WANG Changling, et al. Analysis of the retinal pigment epithelium function in central serous chorioretinopathy[J]. Chinese Journal of Practical Ophthalmology, 2008, 26(11): 1255-1256. doi:10.3760/cma.j.issn.1006-4443.2008.11.030
[41] Pauleikhoff L, Agostini H, Lange C. Central serous chorioretinopathy[J]. Ophthalmologe, 2021, 118(9): 967-980. doi: 10.1007/s00347-021-01376-7
[42] Breukink MB, Mohr JK, Ossewaarde-van Norel A, et al. Half-dose photodynamic therapy followed by diode micropulse laser therapy as treatment for chronic central serous chorioretinopathy: evaluation of a prospective treatment protocol[J]. Acta Ophthalmol, 2016, 94(2): 187-197. doi:10.1111/aos.12938
[43] Pichai J, Vanchalerm B, Mansing R. One-year results of half-dose versus one-third-dose photodynamic therapy in chronic or recurrent central serous chorioretinopathy[J]. BMC Ophthalmol, 2021, 21(1): 30. doi:10.1186/s12886-020-01796-0
[44] Leaver P, Williams C. Argon laser photocoagulation in the treatment of central serous retinopathy[J]. Br J Ophthalmol, 1979, 63(10): 674-677. doi:10.1136/bjo.63.10.674
[45] Wong KH, Lau KP, Chhablani J, et al. Central serous chorioretinopathy: what we have learnt so far[J]. Acta Ophthalmol, 2016, 94(4): 321-325. doi:10.1111/aos.12779
[46] 罗清礼, 王琳, 吴海英. 激光光凝后视网膜色素上皮、Bruch膜和脉络膜超微结构改变[J]. 中华眼科杂志, 2004, 40(10): 692-695. doi:10.3760/j: issn: 0412-4081.2004.10.010 LUO Qingli, WANG Lin, WU Haiying. Ultrastructure study on the RPE, Bruch's membrane and choroid after laser photocoagulation of the Retina[J]. Chinese Journal of Ophthalmology, 2004, 40(10): 692-695. doi:10.3760/j: issn: 0412-4081.2004.10.010
[47] Lim JW, Kang SW, Kim YT, et al. Comparative study of patients with central serous chorioretinopathy undergoing focal laser photocoagulation or photodynamic therapy[J]. Br J Ophthalmol, 2011, 95(4): 514-517. doi:10.1136/bjo.2010.182121
[48] 赵俊华. 中心性浆液性脉络膜视网膜病变治疗方法的研究进展[J]. 中国临床新医学, 2017, 10(8): 816-820. doi:10.3969/j.issn.1674-3806.2017.08.33 ZHAO Junhua. Research progress in the treatment of central serous chorioretinopathy[J]. Chinese Journal of New Clinical Medicine, 2017, 10(8): 816-820. doi:10.3969/j.issn.1674-3806.2017.08.33
[49] Sivaprasad S, Elagouz M, McHugh D, et al. Micropulsed diode laser therapy: evolution and clinical applications[J]. Surv Ophthalmol, 2010, 55(6): 516-530. doi:10.1016/j.survophthal.2010.02.005
[50] 廖丹, 许立帅, 戴乐, 等. 577 nm阈下微脉冲激光治疗黄斑中心凹渗漏的慢性中心性浆液性脉络膜视网膜病变[J]. 眼科新进展, 2018, 38(2): 139-142. doi:10.13389/j.cnki.rao.2018.0030 LIAO Dan, XU Lishuai, DAI Le, et al. Subthreshold micropulse yellow laser(577 nm)for chronic central serous chorioretinopathy with foveal leakage[J]. Recent Advances in Ophthalmology, 2018, 38(2): 139-142. doi:10.13389/j.cnki.rao.2018.0030
[51] 任雨馨, 赵博军. 病理性近视脉络膜新生血管的诊断与治疗[J]. 山东大学耳鼻喉眼学报, 2020, 34(5): 157-162. doi:10.6040/j.issn.1673-3770.0.2019.545 REN Yuxin, ZHAO Bojun. Diagnosis and treatment of choroidal neovascularization in pathologic myopia[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(5): 157-162. doi:10.6040/j.issn.1673-3770.0.2019.545
[52] Ji S, Wei Y, Chen J, et al. Clinical efficacy of anti-VEGF medications for central serous chorioretinopathy: a meta-analysis[J]. Int J Clin Pharm, 2017, 39(3):514-521. doi: 10.1007/s11096-017-0460-4
[53] Song YY, Yu HY, Baek SK, et al. Short-term effect of anti-VEGF for chronic central serous chorioretinopathy according to the presence of choroidal neovascularization using optical coherence tomography angiography[J]. PLoS One, 2021, 16(1): e0245342. doi:10.1371/journal.pone.0245342
[54] Lim JW, Ryu SJ, Shin MC. The effect of intravitreal bevacizumab in patients with acute central serous chorioretinopathy[J]. Korean J Ophthalmol, 2010, 24(3): 155-158. doi:10.3341/kjo.2010.24.3.155
[55] Chrzszcz M, Pociej-Marciak W, Zuber-Łaskawiec K, et al. Changes in plasma VEGF and PEDF levels in patients with central serous chorioretinopathy[J]. Medicina(Kaunas), 2021, 57(10): 1063. doi:10.3390/medicina57101063
[56] Bousquet E, Dhundass M, Lejoyeux R, et al. Predictive factors of response to mineralocorticoid receptor antagonists in nonresolving central serous chorioretinopathy[J]. Am J Ophthalmol, 2019, 198: 80-87. doi:10.1016/j.ajo.2018.09.034
[57] Lotery A, Sivaprasad S, O'Connell A, et al. Eplerenone versus placebo for chronic central serous chorioretinopathy: the VICI RCT[J]. Efficacy Mech Eval, 2021, 8(2): 1-82. doi:10.3310/eme08020
[58] Kurup SK, Oliver A, Emanuelli A, et al. Low-dose methotrexate for the treatment of chronic central serous chorioretinopathy: a retrospective analysis[J]. Retina, 2012, 32(10): 2096-2101. doi:10.1097/IAE.0b013e31825dd281

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed

Comments

Recommended 0

No Suggested Reading articles found!

Research progress on the pathogenesis and treatments of central serous chorioretinopathy

PDF (PC)

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	ZHU Yunlong, WANG Ping, GAO Meng. A case of posterior scleritis initially misdiagnosed as central serous chorioretinopathy and retinitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 99-105.
[2]	LIU Yijie, LU Xiuzhen, WU Qiuxin. Research rogress of exosomes in the pathogenesis, diagnosis and treatment in ophthalmic diseases [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2026, 40(1): 135-141.
[3]	WANG Huanxia, WANG Shuya, WANG Ying, SUN Xuan, HUANG Jie, WANG Xingrong. Risk factors for epiretinal membrane formation following pars plana vitrectomy for rhegmatogenous retinal detachment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(4): 181-185.
[4]	PAN Jiayu, ZHANG Chunlin. Research advances on the etiology and pathogenesis of acute low-frequency sensorineural hearing loss [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2025, 39(2): 126-131.
[5]	WU Wei, WANG Lei, CHEN Sheng, LI Lianyong, WANG Gang. Multidisciplinary research and advances in gastro-oesophageal reflux disease [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(6): 1-14.
[6]	ZHOU Shitong, YANG Yanyan, YANG Yucheng, FANG Hongyan. Pepsin and laryngopharyngeal reflux disease: from pathogenic mechanisms to potential risk factors for pharyngeal and laryngeal squamous cell carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2024, 38(6): 55-60.
[7]	ZHANG Xiaohan, WEI Li, YANG Kaili, CHEN Haiyan, LI Yansong, WANG Ping. Study on the change of OCTA and its correlation with visual acuity in patients with CSC before and after TCM syndrome differentiation and treatment [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(5): 115-122.
[8]	CHEN Zhuoyi, ZHENG Yiqing, YANG Haidi. Classification, pathogenesis, and treatment advances of chronic subjective tinnitus [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 1-12.
[9]	ZHANG Hong, LI Xin. The role and mechanism of abnormal central nervous system activity in the occurrence of tinnitus [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(4): 24-29.
[10]	TANG Huixin, LI Jingjing, ZOU Hong. Mechanism and clinical applications of subthreshold diode micropulse laser [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(3): 143-148.
[11]	XIAO Fuliang, LIN Yun, PAN Xinliang. A clinical study on prophylactic central lymph node dissection in early cN0 papillary thyroid carcinoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2023, 37(1): 64-71.
[12]	WANG Xingxin, YANG Xinyu, ZHENG Xiaojun, DING Lin, SHENG Yawen, BI Xiaoyun, YANG Jiguo. Acupoint application therapy for adenoid hypertrophy in children: a case report [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 122-124.
[13]	ZHANG Lijun, XU Ran, LUO Jifang, LIU Guoqi, HE Qian, LI Wei, JIANG Zhenhua. Factors affecting flap neurosis and other postoperative flap-related complications after free-flap reconstruction of head and neck tumors [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(4): 86-90.
[14]	LIN Hai, ZHU Ying,ZHANG Weitian. The roles of ion channels in the pathogenesis of chronic rhinosinusitis [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 64-70.
[15]	LI Jiani, ZHU Dongdong,MENG Cuida. The role of epigenetics in the pathogenesis of chronic rhinosinusitis with nasal polyps [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(3): 84-91.